An extension of cancer immunotherapy with dostarlimab, the PD1-PD L1 pathway blocker

Cancer immunotherapy is a treatment that uses the body’s own immune system to fight against
cancer. Malignant cells in the human body have the ability to mutate themselves in such a way
that they can escape from immune system surveillance and proliferate. So, if the human immune
system could be boosted or its surveillance and defensive mechanisms improved so that our
bodies can detect cancer cells and kill them by combining all of the human body’s defensive
mechanisms, it would be much easier to deal with cancer. A recent trial at Memorial Sloan
Kettering Cancer Center in New York found that by using a drug called Dostarlimab, rectal
adenocarcinoma could be cured by boosting the human immune system to detect and kill cancer
cells. This could be considered a validated extension of cancer immunotherapy. This paper will
explain how dostarlimab works on the body’s immune system and destroys cancer cells in a
simple way that anyone who is not in the medical field also can understand.